submit url • add directory • Internal Medicine jobs in Chicago ♦ ♦ pediatric jobs ♦ anesthesia jobs
Today's News:
Permanent Oncology Jobs
Oncology jobs
Mon, 21 May 2012 11:48:02 -0500
All Oncology jobs for Mon May 21 2012
Oncology jobs in "Santa Clarita, San Fernando, Mission Hills, Los Angeles" - CA
Thu, 17 May 2012 12:15:44 -0600
Hematologist /Oncologist wanted - Los Angeles’s San Fernando Valley, Live the Los Angeles life style with nearby beaches & mountains and world
Oncology jobs in "Oncology Specialists For Brand New Cancer Center" - OK
Tue, 19 Jul 2011 12:15:44 -0600
Clinician, Educator, Scientist Clinical prestige, ahead-of-the-curve technology and an unrivaled team environment await you at The University of Oklahoma Medical Center. This summer, The Peggy
Annals of Oncology - current issue
DNA ploidy in endometrial cancer: unfinished business?
Terada, K. Tue, 24 Apr 2012 04:59:56 -0700
Recent developments in treatments targeting castration-resistant prostate cancer bone metastases
Loriot, Y., Massard, C., Fizazi, K. Tue, 24 Apr 2012 04:59:56 -0700
Background: Prostate cancer is the most common male cancer and one of the top causes of male cancer-related death. Most patients with prostate cancer respond to initial androgen deprivation therapy before progressing to castration-resistant prostate cancer (CRPC) and eventually developing bone metastases. Growth of prostate cancer metastases in the bone microenvironment produces numerous factors that disrupt the dynamic equilibrium of osteogenesis and osteolysis existing in healthy bone, leading to progressive morbidity, poor quality of life, and increased treatment costs. Materials and methods: Relevant studies of CRPC and targeted therapies were identified from literature and clinical trial databases, websites, and conference abstracts. Results: Available data on agents potentially targeting bone metastatic CRPC or the bone microenvironment in patients with CRPC are discussed, including inhibitors of tumor growth/survival and bone turnover (SRC family kinase inhibitors, endothelin-1 inhibitors, MET inhibitors, and thalidomide and its derivatives), inhibitors of bone turnover (bisphosphonates and receptor activator of nuclear factor-kB ligand inhibitors), antiangiogenic agents (vascular endothelial growth factor receptor and platelet-derived growth factor blockers), prostate cancer vaccines, and bone-directed radiopharmaceuticals. Conclusions: With increasing data availability demonstrating tumor–bone microenvironment interactions and routine incorporation of bone-related end points into CRPC trials, bone microenvironment-targeted agents are likely to become an increasingly important component of CRPC treatment.
Esophageal carcinoma advances in treatment results for locally advanced disease: review
Herskovic, A., Russell, W., Liptay, M., Fidler, M. J., Al-Sarraf, M. Tue, 24 Apr 2012 04:59:56 -0700
The treatment results of patients with locally advanced esophageal carcinomas have evolved since the publication of the first trial of concurrent mitomycin C and 5-fluorouracil with radiotherapy (RT) in 1983. Subsequent studies refined and improved on the concurrent chemotherapy (chemo) with administration of cisplatin and 5-fluorouracil infusion (PF). Chemo (PF) before surgery improved overall survival (OS) in those patients in most of the randomized trials and in meta-analyses. Two courses of PF concurrent with irradiation followed by additional two courses of PF were superior to RT alone without surgery for both groups. Concurrent chemoradiotherapy followed by surgery was found to have statistically improved OS as compared with surgery only in randomized trials and meta-analyses. In most of these studies, it was found that those patients with pathologic complete response to the initial treatment(s) did better than those who had no improvement at all. Current treatment outcome for these diseases is disappointing; newer strategies including induction chemo with the optimal combination, proper dosage of each drug, and proper number of courses before concurrent chemoradiotherapy; improvement in RT; and immunotherapy with or without subsequent surgery are exciting and definitely need to be investigated in prospective randomized trial(s).
Subscribe to Oncology RSS feed 
Oncology jobs
Mon, 21 May 2012 11:48:02 -0500
All Oncology jobs for Mon May 21 2012
Oncology jobs in "Santa Clarita, San Fernando, Mission Hills, Los Angeles" - CA
Thu, 17 May 2012 12:15:44 -0600
Hematologist /Oncologist wanted - Los Angeles’s San Fernando Valley, Live the Los Angeles life style with nearby beaches & mountains and world
Oncology jobs in "Oncology Specialists For Brand New Cancer Center" - OK
Tue, 19 Jul 2011 12:15:44 -0600
Clinician, Educator, Scientist Clinical prestige, ahead-of-the-curve technology and an unrivaled team environment await you at The University of Oklahoma Medical Center. This summer, The Peggy
Annals of Oncology - current issue
DNA ploidy in endometrial cancer: unfinished business?
Terada, K. Tue, 24 Apr 2012 04:59:56 -0700
Recent developments in treatments targeting castration-resistant prostate cancer bone metastases
Loriot, Y., Massard, C., Fizazi, K. Tue, 24 Apr 2012 04:59:56 -0700
Background: Prostate cancer is the most common male cancer and one of the top causes of male cancer-related death. Most patients with prostate cancer respond to initial androgen deprivation therapy before progressing to castration-resistant prostate cancer (CRPC) and eventually developing bone metastases. Growth of prostate cancer metastases in the bone microenvironment produces numerous factors that disrupt the dynamic equilibrium of osteogenesis and osteolysis existing in healthy bone, leading to progressive morbidity, poor quality of life, and increased treatment costs. Materials and methods: Relevant studies of CRPC and targeted therapies were identified from literature and clinical trial databases, websites, and conference abstracts. Results: Available data on agents potentially targeting bone metastatic CRPC or the bone microenvironment in patients with CRPC are discussed, including inhibitors of tumor growth/survival and bone turnover (SRC family kinase inhibitors, endothelin-1 inhibitors, MET inhibitors, and thalidomide and its derivatives), inhibitors of bone turnover (bisphosphonates and receptor activator of nuclear factor-kB ligand inhibitors), antiangiogenic agents (vascular endothelial growth factor receptor and platelet-derived growth factor blockers), prostate cancer vaccines, and bone-directed radiopharmaceuticals. Conclusions: With increasing data availability demonstrating tumor–bone microenvironment interactions and routine incorporation of bone-related end points into CRPC trials, bone microenvironment-targeted agents are likely to become an increasingly important component of CRPC treatment.
Esophageal carcinoma advances in treatment results for locally advanced disease: review
Herskovic, A., Russell, W., Liptay, M., Fidler, M. J., Al-Sarraf, M. Tue, 24 Apr 2012 04:59:56 -0700
The treatment results of patients with locally advanced esophageal carcinomas have evolved since the publication of the first trial of concurrent mitomycin C and 5-fluorouracil with radiotherapy (RT) in 1983. Subsequent studies refined and improved on the concurrent chemotherapy (chemo) with administration of cisplatin and 5-fluorouracil infusion (PF). Chemo (PF) before surgery improved overall survival (OS) in those patients in most of the randomized trials and in meta-analyses. Two courses of PF concurrent with irradiation followed by additional two courses of PF were superior to RT alone without surgery for both groups. Concurrent chemoradiotherapy followed by surgery was found to have statistically improved OS as compared with surgery only in randomized trials and meta-analyses. In most of these studies, it was found that those patients with pathologic complete response to the initial treatment(s) did better than those who had no improvement at all. Current treatment outcome for these diseases is disappointing; newer strategies including induction chemo with the optimal combination, proper dosage of each drug, and proper number of courses before concurrent chemoradiotherapy; improvement in RT; and immunotherapy with or without subsequent surgery are exciting and definitely need to be investigated in prospective randomized trial(s).
Sites:
ACS Online CME: Web site for ACS Online CME.Advances in Oncology: Cancer treatments for chronic myeloid leukemia, breast cancer and other cancer types. Research on bone cancer symptoms - brain cancer and leukemia or CML info.
California Oncology Consortium: California Oncology Consortium is an advocate for the practicing oncologist and their patients. We represent the oncology community before legislature, Medicare and insurance carriers.
Crossroads Cancer Consulting: Offers strategic planning for oncology programs. Includes trends, articles, and links to oncology related sites.
European School of Oncology(ESO): Educational resource for oncologists
FDA Oncology Tools: Oncology Tools
General Practice Notebook - Oncology: Coverage of this medical speciality.
Hematology-Oncology Resource Centers: The Hematology/Oncology section of Medscape.com with many useful information primarily intended for healthcare professionals.
Hyperthermia in Modern Oncology: local and whole body hyperthermia as successful intensification of the cytotoxic effect of chemotherapy in complex less toxic therapeutic strategy against widely disseminated and multidrug resistant tumors, in combination with immune therapy and advanced biologic and holistic approach
International Network for Cancer Treatment and Research (INCTR): The INCTR assists developing countries by supporting research collaboration, education and training in oncology with the aim of increasing survival rates and the quality of life.
International Society of Geriatric Oncology (SIOG): Dedicated the advancement of oncology in elderly patients
Medscape Oncology: Medscape Hematology-Oncology is a free resource for Physicians, featuring Free Hematology-Oncology CME (Continuing Medical Education), Hematology-Oncology medical journal articles, MEDLINE, Hematology-Oncology medical news, major Hematology-Oncology conference coverage, and comprehensive drug inf...
National Cancer Institute - Cancer Statistics: NCI's gateway to information on cancer statistics for the public, health professionals, and researchers. Includes a glossary of terms, reports of cancer rates and trends, and tools and software aids for data analysis.
Network for Oncology Communication and Research: Oncology
Oncology Jobs: Physician jobs for all specialties throughout North America.
Oncology Resource Consultants, Inc.: Cancer consulting from Oncology Resource Consultants specializing in cancer planning and cancer reimbursement.
Oncology.com: Comprehensive cancer and medical resources, including databases on alternative cancer treatments, medical terminology, chemotherapy and other drugs, and links to scientific journals.
Surveillance, Epidemiology, and End Results (SEER): The SEER program provides information on cancer statistics to help reduce the burden of cancer on the U.S. population. SEER collects and publishes cancer incidence and survival data from population-based cancer registries.
This directory is based on the Open Directory and may have been modified